市场调查报告书
商品编码
1388284
前列腺特异性抗原测试市场 - 按测试类型(初步{总、复杂、免费}、确认性{PCA3、活检})、按应用(筛检、监测)、按最终用途(医院、专科诊所、诊断中心) - 2023-2032 年全球预测Prostate-Specific Antigen Test Market - By Test Type (Preliminary {Total, Complex, Free}, Confirmatory {PCA3, Biopsy}), By Application (Screening, Monitoring), By End-use (Hospitals, Specialty Clinics, Diagnostic Centers) - Global Forecast, 2023-2032 |
在向综合诊断方法(包括验证性检测)持续转变的推动下,前列腺特异性抗原检测市场规模从 2023 年到 2032 年将以 8.3% 的CAGR扩大。最近,世界各地的医疗保健提供者越来越多地采用几种前列腺健康的整体方法,例如将前列腺特异性抗原(PSA)测试整合到更广泛的诊断策略中。这一转变强调了早期检测和个人化治疗计划的重要性,进一步增加了预防性护理中对 PSA 检测的需求。
随着对前列腺健康的科学认识不断进步,研究人员正致力于开发创新疗法和药物。例如,2023 年11 月,根据3 期EMBARK 试验的结果,安斯泰来製药和辉瑞获得美国FDA 批准XTANDI (R)(恩杂鲁胺)的补充新药申请,这是一种有前景的前列腺癌治疗选择患者。因此,随着此类研发工作的开展,对 PSA 检测的需求也在增加,因为准确的诊断对于监测治疗效果至关重要。
PSA 测试产业分为测试类型、应用、最终用途和区域。
根据测试类型,确认性细分市场的市场规模预计从 2023 年到 2032 年将以 8.7% 的CAGR成长。确认性测试(包括 PCA3 和活检)对于在检测到 PSA 水平升高后提供准确和结论性的结果至关重要。对精准医疗和个人化治疗计划的日益重视也增强了前列腺健康诊断中验证性测试的重要性。此外,医疗保健提供者越来越多地采用综合诊断方法将推动该细分市场的成长。
就最终用途而言,医院领域的前列腺特异性抗原检测行业预计在 2023 年至 2032 年间将增长 8.3%。由于医院拥有全面的医疗保健基础设施,因此成为包括 PSA 检测在内的诊断程序的主要中心。前列腺相关疾病发生率的上升和人口老化的加剧也导致对常规 PSA 筛检的需求不断增加。此外,医院环境中对早期检测和癌症预防计划的重视将促进该细分市场的成长。
从地区来看,亚太地区PSA 检测行业在2022 年占据了相当大的收入份额,预计到2032 年增长率将超过9%。意识的提高、人口老龄化以及前列腺相关疾病的日益流行正在推动对PSA的需求在该地区进行测试。此外,政府和医疗机构正在积极推动早期检测和筛检计画。诊断程序的技术进步和对男性健康的更加重视也将有助于 PSA 检测的广泛采用。
Prostate-Specific Antigen Test Market size is set to expand at 8.3% CAGR from 2023 to 2032, driven by the ongoing shift towards comprehensive diagnostic approaches, including confirmatory tests. Of late, healthcare providers worldwide are increasingly embracing several holistic approaches to prostate health, such as integrating prostate-specific antigen (PSA) testing into broader diagnostic strategies. This shift is emphasizing the significance of early detection and personalized treatment plans, further surging the demand for PSA tests in preventive care.
With rising advances in scientific understanding of prostate health, researchers are focusing on developing innovative therapies and drugs. For instance, in November 2023, based on the outcomes of the Phase 3 EMBARK trial, Astellas Pharma and Pfizer received approval from the U.S. FDA for a supplemental New Drug Application for XTANDI® (enzalutamide), a promising treatment option for prostate cancer patients. The need for PSA tests is hence rising in tandem with such R&D efforts as accurate diagnostics are essential for monitoring treatment efficacy.
The PSA test industry is segmented into test type, application, end-use, and region.
Based on test type, the market size from the confirmatory segment is anticipated to gain 8.7% CAGR from 2023-2032. Confirmatory tests, including PCA3 and biopsy, are essential in providing accurate and conclusive results after an elevated PSA level is detected. The growing emphasis on precision medicine and personalized treatment plans is also enhancing the significance of confirmatory tests in prostate health diagnostics. Moreover, the growing adoption of comprehensive diagnostic approaches by healthcare providers will fuel the segment growth.
In terms of end-use, the prostate-specific antigen test industry from the hospitals segment is expected to witness 8.3% growth rate between 2023 and 2032. Hospitals serve as primary hubs for diagnostic procedures, including PSA testing, due to their comprehensive healthcare infrastructure. The rising incidence of prostate-related disorders and the increasing aging population are also contributing to the increasing demand for routine PSA screenings. Furthermore, the emphasis on early detection and cancer prevention programs within hospital settings will boost the segment growth.
Regionally, the Asia Pacific PSA test industry held sizable revenue share in 2022 and is poised to depict over 9% growth rate through 2032. Increasing awareness, the rising aging population, and the growing prevalence of prostate-related disorders are driving the demand for PSA testing in the region. Additionally, governments and healthcare organizations are actively promoting early detection and screening programs. Technological advancements in diagnostic procedures and the greater emphasis on men health will also contribute to the expanding adoption of PSA tests.